Outlook Therapeutics Inc

+0.01 (+0.46%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)378.46M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.33 Million
Adjusted EPS-$0.10
See more estimates
10-Day MA$2.22
50-Day MA$2.16
200-Day MA$1.45
See more pivots

Outlook Therapeutics Inc Stock, NASDAQ:OTLK

4260 US Route 1, Monmouth Junction, South Brunswick, New Jersey 08852
United States of America
Phone: +1.609.619.3990
Number of Employees: 8


Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in South Brunswick, NJ.